1h Free Analyst Time
Retinoic Acid Receptor Alpha - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis.
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 14 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 2, 5 and 3 respectively. The report covers products from therapy areas Dermatology, Oncology, Immunology, Ophthalmology, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Male Health and Metabolic Disorders which include indications Acne Vulgaris, Acute Promyelocytic Leukemia, Bronchopulmonary Dysplasia, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Batten Disease, Breast Cancer, Chronic Myelomonocytic Leukemia (CMML), Germ Cell Tumors, Inflammatory Bowel Disease, Male Contraception, Myeloproliferative Disorders, Neuroblastoma, Neutropenia, Psoriasis, Retinopathy Of Prematurity, Sarcomas, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
The latest report Retinoic Acid Receptor Alpha - Pipeline Review, H1 2020, outlays comprehensive information on the Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
- The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Io Therapeutics Inc
- Novartis AG
- Orphagen Pharmaceuticals Inc
- Orphanix GmbH
- Ortho Dermatologics Inc
- Polaryx Therapeutics Inc
- Selphagy Therapeutics Inc
- Sol-Gel Technologies Ltd
- Sunny BioDiscovery Inc
- TherapyX Inc
- Toko Pharmaceutical Industries Co Ltd
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles
- (benzoyl peroxide + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (benzoyl peroxide + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (gemfibrozil + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (TPX-6001 + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IRX-5183 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- OR-812 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SBD-073 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic Leukemia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tamibarotene - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tazarotene - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products
- Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones
- Featured News & Press Releases
- Jan 21, 2020: Sol-Gel announces presentation on Twyneo at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
- Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)
- Jan 12, 2020: Syros announces new update on SY-1425
- Jan 08, 2020: Sol-Gel hosts investor call to discuss positive results from Twyneo phase 3 program in Acne Vulgaris
- Dec 30, 2019: Sol-Gel announces positive top-line phase 3 trial results of Twyneo for the treatment of acne vulgaris
- Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
- Oct 24, 2019: Syros Announces new data from phase 2 trial of SY-1425 in combination with azacitidine demonstrating high response rates, rapid onset of action and favorable tolerability profile in RARA-Positive Newly Diagnosed Unfit AML Patients
- Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
- Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
- Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
- Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-1425
- Jul 09, 2019: GSK's Alitoc becoming salvation treatment for chronic hand eczema patients
- Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris
- Jan 06, 2019: Syros provides update on its acute myeloid leukemia drug candidate SY-1425
- Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Information
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Advent Therapeutics Inc, H1 2020
- Pipeline by Avecho Biotechnology Ltd, H1 2020
- Pipeline by Io Therapeutics Inc, H1 2020
- Pipeline by Novartis AG, H1 2020
- Pipeline by Orphagen Pharmaceuticals Inc, H1 2020
- Pipeline by Orphanix GmbH, H1 2020
- Pipeline by Ortho Dermatologics Inc, H1 2020
- Pipeline by Polaryx Therapeutics Inc, H1 2020
- Pipeline by Selphagy Therapeutics Inc, H1 2020
- Pipeline by Sol-Gel Technologies Ltd, H1 2020
- Pipeline by Sunny BioDiscovery Inc, H1 2020
- Pipeline by TherapyX Inc, H1 2020
- Pipeline by Toko Pharmaceutical Industries Co Ltd, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Mechanism of Actions, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Io Therapeutics Inc
- Novartis AG
- Orphagen Pharmaceuticals Inc
- Orphanix GmbH
- Ortho Dermatologics Inc
- Polaryx Therapeutics Inc
- Selphagy Therapeutics Inc
- Sol-Gel Technologies Ltd
- Sunny BioDiscovery Inc
- TherapyX Inc
- Toko Pharmaceutical Industries Co Ltd
